Life Sciences

A new drug can take over a decade and billions of dollars to reach patients, and most of that time isn't spent on the breakthrough science — it's spent on trial logistics, regulatory documentation, and reconciling data that lives in a dozen disconnected systems. The science is hard enough without the data being hard too.

Key Challenges

Fragmented Clinical Trial Data

Trial data is scattered across CROs, sites, labs and EDC systems, making it slow and error-prone to get a single, trusted view of a study's progress or safety signals.

Regulatory and GxP Compliance

FDA, EMA and other regulators expect validated systems, full audit trails and 21 CFR Part 11 compliance — requirements that most legacy infrastructure wasn't built to meet without heavy manual overhead.

Pharmacovigilance Volume

Adverse event reports keep growing in volume and complexity, and manual triage struggles to keep pace without risking missed safety signals or compliance gaps.

Supply Chain and Cold-Chain Visibility

Biologics and temperature-sensitive therapies need supply chain visibility end to end; a break in that visibility risks product integrity and patient safety alike.

AI Impact: Use Cases

AI-Accelerated Discovery

Machine learning models screen and prioritize molecular candidates far faster than traditional wet-lab-only approaches, shrinking early-stage discovery timelines.

Trial Site and Patient Matching

Predictive models match patients to trials and identify high-performing sites, reducing recruitment delays that are one of the biggest sources of trial slippage.

Automated Pharmacovigilance Triage

AI-assisted adverse event detection flags high-priority safety signals for human review, instead of a human reading every report with equal weight.

Demand and Supply Forecasting

Predictive models forecast manufacturing and distribution needs, reducing both stockouts of critical therapies and costly overproduction.

How We Can Help